Lupin Share Price: Brokerage ne target cut kiya, kya investors ko abhi bechna chahiye?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Lupin Share Price: Brokerage ne target cut kiya, kya investors ko abhi bechna chahiye?
Overview

Systematix ne Lupin Ltd. ka target price ₹2,408 par set kiya hai, aur 'Hold' rating maintain rakhi hai. Brokerage ko future mein, khaas kar FY27 mein, gTolvaptan jaise bade products par competition ki wajah se thoda pressure dikh raha hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Systematix ne actually Lupin ka target price ₹2,454 se kam karke ₹2,408 kar diya hai, aur 'Hold' rating rakhi hai. Unhone FY28 ke liye EPS forecast bhi 2% kam kar diya hai. Yeh sab Lupin ke Q4 FY26 ke results aane ke baad hua, jisme company ka revenue 32% badh kar ₹74,747 million ho gaya tha. Profit after tax bhi 89% jump karke ₹14,603 million pahunch gaya aur EBITDA 68% badha.

Lekin Systematix ko lagta hai ki FY27 se gTolvaptan, jo Lupin ka sabse bada product hai, us par competition aa jayegi. Uske baad FY28 ke second half mein gMirabegron par bhi competition ka risk hai. Isse short-term earnings par effect pad sakta hai.

Par FOMO nahi! Systematix ko FY28 ke baad growth wapas aane ki poori umeed hai. Yeh growth unke biosimilar pipeline se aayegi, jisme Pegfilgrastim, ranibizumab, aur etanercept jaise products hain. Respiratory inhaler approvals bhi help karenge, jaise gDulera.

Lupin filhaal aur bhi respiratory inhalers jaise Spiriva Respimat, Symbicort, aur Advair HFA ke liye regulatory filings kar raha hai. Ye products aane wale 2-4 saalon mein revenue generate karna shuru kar sakte hain.

Aur haan, Nirmal Bang ka bhi forecast hai ki FY26-28 mein Lupin ka revenue 4% badhega, lekin EBITDA -8% aur PAT -13% ho sakta hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.